Gilotrif FDA Approval History
FDA Approved: Yes (First approved July 12, 2013)
Brand name: Gilotrif
Generic name: afatinib
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Development Timeline for Gilotrif
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.